**Hologic Captures 18% of Global Women’s Health Devices Market**
Hologic (HOLX) held a significant 18% share of the global women’s health devices market in 2025, according to Global Market Insights. The market is expected to grow at a compound annual growth rate (CAGR) of 10.2% from 2026 to 2035, driven by an increase in gynecological disorders, greater awareness of preventive healthcare, and a rising demand for minimally invasive treatments. In Q1 of fiscal 2026, Hologic’s GYN Surgical segment generated $180.8 million in revenue, a 7.5% increase year-over-year, bolstered by sales of MyoSure and Fluent devices, alongside the recently acquired Gynesonics business.
Hologic’s international investments have expanded the reach of its minimally invasive surgical products, with MyoSure now gaining more market share abroad than in the U.S. The company has also seen double-digit growth for its NovaSure product and introduced the Sonata system through the Gynesonics acquisition to further enhance its offerings for treating symptomatic uterine fibroids. Competitors include Medtronic and Johnson & Johnson, with Medtronic recently launching its robotic-assisted surgery system for gynecological procedures.
In the past year, Hologic’s stock has risen by 20.7%, outperforming the industry, which experienced a 3.8% decline. Currently, HOLX is trading at a forward price-to-sales ratio of 3.88, with a Zacks Rank of #4 (Sell).
